In their study, Broccoli et al. (2025) discuss the efficacy of second-generation Bruton tyrosine kinase (BTK) inhibitors, with a particular focus on zanubrutinib, in the treatment of mantle cell lymphoma (MCL). These inhibitors are designed to be highly selective, targeting the BTK enzyme that is crucial for the growth and survival of cancerous B-cells. The improved selectivity of second-generation BTK inhibitors means they have fewer unintended effects on other targets and tissues, which translates to better patient tolerability and a more favorable therapeutic index compared to first-generation inhibitors.
The paper highlights the advancements in BTK inhibitor therapy, emphasizing the potential benefits of zanubrutinib for patients with MCL. By honing in on the specific enzyme implicated in the disease, zanubrutinib promises to offer a more precise treatment option, potentially improving outcomes for those affected by this type of lymphoma. The research underscores the importance of continued development in targeted therapies for hematologic malignancies.
